ProCE Banner Activity

COMMANDS: Long-term Outcomes of the Phase III Trial of Luspatercept vs Epoetin alfa for ESA-Naive, Transfusion-Dependent, Lower-Risk MDS

Conference Coverage
Slideset

Long-term follow-up results from the phase III COMMANDS trial demonstrated significantly higher rates of RBC-TI ≥1 year and ≥1.5 years with luspatercept compared with epoetin alfa among patients with ESA-naive, transfusion-dependent, low-risk to intermediate-risk MDS.

Released: December 09, 2024

Expiration: December 08, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation